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Simčič S, Stopinšek S, Markelj G, 
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Background: Prevalence of complement deficiencies (CDs) is markedly higher in 
Slovenian primary immunodeficiency (PID) registry in comparison to other national and 
international PID registries.
Objective: The purposes of our study were to confirm CD and define complete and par-
tial CD in registered patients in Slovenia, to evaluate frequency of clinical manifestations, 
and to assess the risk for characteristic infections separately for subjects with complete 
and partial CD.
Methods: CD was confirmed with genetic analyses in patients with C2 deficiency, C8 
deficiency, and hereditary angioedema or with repeated functional complement studies 
and measurement of complement components in other CD. Results of genetic studies 
(homozygous subjects vs. heterozygous carriers) and complement functional studies 
were analyzed to define complete (complement below the level of heterozygous carriers) 
and partial CD (complement above the level of homozygous patients). Presence of char-
acteristic infections was assessed separately for complete and partial CD.
results: Genetic analyses confirmed markedly higher prevalence of CD in Slovenian PID 
registry (26% of all PID) than in other national and international PID registries (0.5–6% 
of all PID). Complement functional studies and complement component concentrations 
reliably distinguished between homozygous and heterozygous CD carriers. Subjects 
with partial CD had higher risk for characteristic infections than previously reported.
conclusion: Results of our study imply under-recognition of CD worldwide. Complement 
functional studies and complement component concentrations reliably predicted risk 
for characteristic infections in patients with complete or partial CD. Vaccination against 
encapsulated bacteria should be advocated also for subjects with partial CD and not 
limited to complete CD.
Keywords: complement deficiency, primary immunodeficiency, laboratory analysis, genetic analysis, clinical 
manifestations
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inTrODUcTiOn
Complement is a cascade of soluble proteins and membrane 
expressed receptors and regulators, playing a key role in host 
homeostasis, inflammation, and defense against pathogens. The 
complement cascade can be activated by classical, alternative 
and lectin pathways leading to activation of anaphylatoxins 
C3a and C5a, opsonins C3b and C5b. Deposition of C5b onto a 
target initiates membrane attack complex (consisting of C5–C9 
components) formation and target lysis (1). It is well recognized 
that homozygous mutations in complement component C1–C9 
genes severely reduce complement activity and lead to recurrent 
infections with encapsulated bacteria and autoimmune phenom-
ena (2, 3). However, the expressivity of complement deficiencies 
(CDs) could range from absence of clinical manifestations to 
death because of bacterial meningitis, pneumonia or sepsis in 
C1–C9 deficiencies and life-threatening edema in hereditary 
angioedema (HAE) (4).
According to published data, heterozygous mutations in com-
plement component C1–C9 genes partially reduce complement 
activity that only exceptionally leads to clinical manifestations 
(5). However, the correlation between homozygous and heterozy-
gous states, complement activity and clinical manifestations in a 
large cohort has not been studied yet. Published data are limited 
to small case series and 1 multicenter study evaluating clinical 
manifestations in 77 patients with CD (excluding HAE, MBL 
deficiency, and CD carriers) from 18 cities across Europe (6). 
However, CD was genetically confirmed in only 25% of included 
patients and the study did not evaluate the correlation between 
complement activity and clinical manifestations.
We present data from the largest single center cohort of 
patients with primary CD (homozygous or compound het-
erozygous mutation in C1–C9 genes and HAE) and CD carriers 
(heterozygous mutations in C1–C9 genes), including demo-
graphic data, genetic characteristics, complement activity, and 
clinical manifestations. The study was designed as long-term 
cohort study specifically addressing the correlation between 
homozygous and heterozygous states and complement activ-
ity, the impact of complete and partial CD on the long-term 
outcome in patients with CD (excluding HAE), correlation 
between specific mutations in C2 (including 2 novel mutations) 
and complement activity, as well as prevalence and clinical 
manifestations of HAE.
MaTerials anD MeThODs
study Design
The study design was a national cohort study of all CD patients 
(excluding MBL deficiency and atypical hemolitic uremic syn-
drome without genetic defect in complement factors) included 
in the Slovenian national primary immunodeficiency (PID) 
registry and carriers of CD. The Slovenian national PID registry 
was established in 2007 and compiles data of all patients with 
PID evaluated at the secondary and tertiary care hospitals in 
Slovenia since January 1977. The methodology of the registry was 
described elsewhere (7). See supplementary material for detailed 
description of methods.
In Slovenia, complement activity is routinely measured in 
most patients after the first infection with Neisseria meningitidis 
and after recurrent infections with other encapsulated bacteria 
(Streptococcus pneumoniae and Haemophilus influenzae type 
b) after neonatal period or autoimmune diseases, especially 
connective tissue diseases and glomerulonephritis. CDs (except 
HAE) were diagnosed in case of persistently reduced comple-
ment activation and reduced concentration of complement 
component in the absence of signs of complement consumption 
[e.g., in systemic lupus erythematosus (SLE); except in patients 
with SLE with confirmed genetic defect in the complement 
system] or reduced complement production (e.g., liver disease). 
The diagnosis of HAE was established in the presence of at least 
one major clinical criterion (cutaneous angioedema, abdominal 
pain, laryngeal edema) and one laboratory criterion (reduced C1 
inhibitor concentration, reduced C1 inhibitor function, or identi-
fied mutation in C1 inhibitor or FXII) as proposed in guidelines 
for diagnosis of HAE (8, 9).
Prevalence of CD and prevalence of all PID in Slovenia were 
calculated and compared to prevalence of CD in other national 
registries and the European Society for Immunodeficiencies 
(ESID) registry. Demographic characteristics and clinical mani-
festations leading to diagnosis were analyzed. In patients with 
HAE, clinical severity score was calculated based on the age of 
disease onset, number of organs affected and need for long-term 
prophylaxis and expressed with values from 0 to 10 (10). Data on 
mortality related to CD (death because of HAE attack or severe 
infection in other CD) in registered patients or their family 
members were analyzed.
study Participants
Two hundred fifty-seven patients with 51 different PID were 
registered in the Slovenian PID registry between January 
1977 and January 2017 (152 male, 105 female; 22% adults). 
Seventy-five (29%) patients were diagnosed in the last 5 years. 
Sixty-eight patients with six different CD (HAE, C2, C6, C7, 
C8, and properdin deficiency) were registered in the Slovenian 
PID registry during the study period (33 male, 35 female, 73% 
adults), which represented 26% of all registered PID patients. 
Clinical data on 17 patients with HAE were published before 
(11), in the present article the data are supplemented with 
patients diagnosed after year 2012. At the time of the study, 
the majority of patients with HAE were adults (96%—23 of 24 
patients); median age 49  years (6–90  years), which contrasts 
with other CD where adults represented 61% of the enrolled 
patients (27 of 44 patients). Average age at the first manifes-
tation of complement component deficiency was 2.9  years 
(0.1–24 years; data available for 17 patients), whereas in HAE, 
it was higher, 17 (3–59) years. Average delay in the diagnosis 
of CD and HAE were 1.4 (0–12) years and 8.5 (6–36) years, 
respectively.
The genetic defect in the complement system was con-
firmed in 23/24 (96%) patients with HAE and in 20/44 (45%) 
of patients with other CD, respectively (24 patients were not 
genetically evaluated, because DNA or consent for genetic 
testing were not available). Genetic testing confirmed homozy-
gous or compound heterozygous mutation in all subjects in 
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whom C2 or C8 deficiency was previously diagnosed with 
functional tests. Of 44 patients with CD other than HAE, 20 
had C8 deficiency, 18 had C2 deficiency, 2 had C6 deficiency, 
2 had C7 deficiency, 1 had combined C6/C7 deficiency, and 1 
had properdin deficiency. Of 24 patients with HAE, 17 patients 
from 9 families were diagnosed with HAE type I and 7 patients 
from 4 families with HAE type II. We also identified three 
patients in one family with HAE with normal C1 inhibitor and 
mutation in FXII.
Besides 68 patients with CD, we identified 20 carriers of CD 
(16 carriers with mutation in the C2 gene and 4 carriers with 
mutation in the C8 gene) and 4 subjects with complement levels 
characteristic for carrier state but without confirmed genetic 
mutation. Most carriers were diagnosed during evaluation of 
family members of patients with CD; however in two participants, 
carrier state was diagnosed during evaluation of suspected PID. 
Clinical data of 16 patients with complement component defi-
ciency diagnosed before the year 1995 were not available, these 
participants were included only in the epidemiological analysis 
but not in the analysis of associations between complement activ-
ity and clinical manifestations.
All patients or their legal guardians gave informed consent 
for data collection, which was approved by the National Medical 
Ethics Committee. The study has been carried out in accordance 
with the Declaration of Helsinki.
correlation Between homozygous/
heterozygous Mutations in cD (excluding 
hae) and Functional complement Tests 
and concentrations of affected 
complement components
In the first part of the study, we analyzed if it is possible to predict 
genetic status of C2 and C8 with functional complement studies 
by comparing results of functional complement tests (CH50, 
AH50) and concentrations of C2 and C8 complement compo-
nents between the following:
 (a) patients with homozygous or compound heterozygous muta-
tions causing complement component deficiency and
 (b) carriers of heterozygous mutation causing complement 
component deficiency.
Following analyses were performed:
 (a) CH50 in all subjects with C2 deficiency and in all subjects 
with C8 deficiency and
 (b) AH50 in all subjects with C8 deficiency.
In C2 deficiency, only CH50 was analyzed as AH50 is not 
affected by C2. The number of subjects with deficiencies of 
other components of complement were too small for statisti-
cal analysis; therefore, they were presented in a descriptive 
manner.
impact of reduced complement activity 
on long-Term Outcome
In the second part of the study, we analyzed impact of reduced 
complement activity (HAE patients excluded) on long-term 
outcome by comparing subjects with different complement 
levels:
 (a) complete CD: CH50 below the lowest CH50 in carriers of 
mutation causing C2 or C8 deficiency or AH50 below the 
lowest AH50 in C8 deficiency and
 (b) partial CD: CH50 above the lowest CH50 in carriers of muta-
tion causing C2 or C8 deficiency or AH50 above the lowest 
AH50 in C8 deficiency.
Results of functional complement tests (CH50, AH50) and 
concentrations of C2 and C8 complement components were 
compared between the following:
 (a) patients with complete CD with infections;
 (b) subjects with complete CD without infections;
 (c) patients with partial CD with infections;
 (d) subjects with partial CD without infections.
Following analyses were performed:
 (a) CH50 in all subjects with CD (except 1 patient with prop-
erdin deficiency), separately for subjects with C2 and C8 
deficiency;
 (b) AH50 in all subjects with CD, separately for subjects with C2 
and C8 deficiency;
 (c) C2 in subjects with C2 deficiency
 (d) C8 in subjects with C8 deficiency.
Patient samples with deficiencies of other components of 
complement were too small for statistical analysis (six patients 
with infections and one carrier without infections).
correlation Between complement activity 
and specific Mutations in C2 gene, 
including novel Mutations (c.1754c>T and 
c.2024g>T)
Results of functional complement tests (CH50, AH50) and 
concentrations of C2 complement components were compared 
between the following:
 (a) subjects with common homozygous deletion of 28 bp in C2 
(c.841_849 + 19del);
 (b) subjects with compound homozygous mutation in C2 
(c.841_849 + 19del and c.1754C>T);
 (c) subjects with compound heterozygous mutation in C2 
(c.841_849 + 19del + c.945G>C and c.1754C>T)
 (d) a subject who is a carrier of mutation in C2 (c.2024G>T).
statistical Methods
Average values of functional tests (CH50 and AH50) of comple-
ment activation and concentrations of complement components 
were calculated in all included subjects (only measurements 
after the first year of age were taken into account). Differences 
between groups were analyzed using the Student’s t-test for 
independent samples (Welch’s t test). Differences between 
groups are shown in box plots, where thick line represents the 
median; bottom and upper lines the 25th and the 75th percen-
tile, respectively; and the “whiskers” the lowest and the highest 
FigUre 1 | Distribution of primary immunodeficiencies (PIDs) in the Slovenian PID registry. Combined immunodeficiencies: severe combined immunodeficiency, 
combined immunodeficiency; well-defined syndromes: DiGeorge, ataxia-telangiectasia, hyper IgE. Wiskott-Aldrich, Nijmegen, Netherton, Schimke, osteopetrosis; 
antibody deficiencies: x-linked agammaglobulinemia, common variable immunodeficiency. IgA deficiency, class switch defect; immune dysregulation: autoimmune 
lymphoproliferative syndrome; candidiasis, ectodermal dysplasia; x-linked lymphoproliferative syndrome, familial hemophagocytic lymphohistiocytosis autoimmune 
lymphoproliferative syndrome, MALT1 deficiency, Chediak-Higashi, AEP2/3 deficiency; phagocytic defects: chronic granulomatous deficiency, congenital 
neutropenia, Papillon-Lefevre, Schwachman-Diamond, Barth; defects of innate immunity: NEMO deficiency; autoinflammatory syndromes: chronic recurrent 
multifocal osteomyelitis, cryopyrin-associated periodic syndrome, TNF-alpha receptor-associated periodic syndrome; complement deficiencies: C1–C9 deficiencies, 
hereditary angioedema, properdin deficiency.
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values. Dotted lines represent lower and upper normal limits 
of the test.
resUlTs
Distribution of PID in Slovenian PID registry according to 
International union of immunological societies expert committee 
classification (12) is shown in Figure 1.
clinical Manifestations of Patients  
With cD
Only 28/44 patients with CD were evaluated for the clinical 
manifestations because data were not available for the 16 
diagnosed before 1995. CD was diagnosed in 23 of 28 (82%) 
patients with CD excluding HAE after the occurrence of bac-
terial infections, predominantly with encapsulated bacteria 
(S. pneumoniae, H. influenzae, N. meningitidis), Staphylococcus 
aureus, and Streptococcus pyogenes and only in 1/28 patient 
after autoimmune glomerulonephritis (Table 1). CD was also 
diagnosed in six relatives of patients with CD, four of these 
had clinical manifestations consistent with CD. HAE was 
diagnosed in 22 of 24 patients after angioedema. Median 
clinical severity score in HAE was 5 (0–10), with 15 patients 
having peripheral edema (13 facial edema, 6 laryngeal edema, 
11 abdominal pain).
clinical characteristics of carriers of 
Mutations causing cD
Carrier state for CD (excluding HAE) was diagnosed in 22 
subjects evaluated as relatives of patients with CD. Three out 
of 22 (14%) carriers had clinical manifestations consistent with 
CD: bacterial meningitis, recurrent sinusitis, and recurrent skin 
abscesses. Other CD carriers (19/22, 86%) have not had clini-
cal manifestations suggestive of CD until the end of the study. 
Carrier state for CD was confirmed in additional two patients 
who were evaluated for suspected PID because of recurrent 
otitis media and recurrent skin abscesses. Cumulatively, 5/24 
(21%) of CD carriers had characteristic infections by the end 
of the study.
Mortality in cD
None of the patients or carriers of CD from the Slovenian PID 
registry died because of CD; however, three relatives of regis-
tered patients died because of clinical manifestations possibly 
related to CD. A sister of a patient with C2 deficiency died 
from H. influenzae type b meningitis at the age of 2 months; 
two uncles of patients with HAE died from laryngoedema 
(one during dental procedure). Since these relatives were not 
evaluated for PID they were not included in the national PID 
registry.
comparison of results of Functional 
complement assays Between subjects 
With homozygous or compound 
heterozygous C2 or C8 Mutations and 
carriers of heterozygous Mutation 
causing c2 or c8 Deficiency
Subjects with homozygous or compound heterozygous mutations 
in C2 consistently had CH50 below the lower normal limit and 
TaBle 1 | Clinical manifestations and genetic defects in symptomatic patients and carriers of complement deficiency excluding hereditary angioedema.
complement def. Mutation gender age (years) clinical manifestations
Patients with c2, c6, c6/c7, c8 and properdin deficiency and clinical manifestations
C2 deficiency Homozygous c.841_849 + 19del M 16 Sepsis
C2 deficiency homozygous c.841_849 + 19del M 12 Recurrent pneumonia, otitis and sepsis
C2 deficiency Homozygous c.841_849 + 19del M 12 Recurrent pneumonia
C2 deficiency Homozygous c.841_849 + 19del + c.945G>C M 11 Pneumonia and recurrent sepsis
C2 deficiency Homozygous c.841_849 + 19del + c.945G>C M 6 Sepsis and osteomyelitis
C2 deficiency Homozygous c.841_849 + 19del + c.945G>C M 4 Impetigo, recurrent pneumonia and preseptal cellulitis
C2 deficiency Compound heterozygous c.841_849 + 19del and 
c.1754C>T
M 5 Sepsis and nephrotic syndrome
C2 deficiency N.A. M 20 Purulent meningitis
C2 deficiency Compound heterozygous c.841_849 + 19del and 
c.1754C>T
F 9 Recurrent otitis
C2 deficiency Compound heterozygous 
c.841_849 + 19del + c.945G>C and c.1754C>T
F 5 Sepsis and recurrent pneumonia
C2 deficiency Homozygous c.841_849 + 19del F 7 Sepsis and preseptal cellulitis
C8 deficiency Homozygous c1282C>T M 57 Recurrent pneumonia and recurrent purulent meningitis
C8 deficiency Homozygous c1282C>T M 9 Recurrent otitis
C8 deficiency Homozygous c1282C>T F 28 Recurrent pneumonia and recurrent purulent meningitis
C8 deficiency Homozygous c1282C>T F 20 Pneumonia
C8 deficiency Homozygous c1282C>T F 7 Sepsis, sinusitis and recurrent otitis
C8 deficiency Homozygous c1282C>T F 9 Pneumonia
C8 deficiency Homozygous c1282C>T F 30 Purulent meningitis
C8 deficiency Homozygous c1282C>T F 35 Purulent meningitis
C8 deficiency Homozygous c1282C>T F 32 Purulent meningitis
properdin def. N.A. M 27 Purulent meningitis
C7 deficiency N.A. F 28 Recurrent sepsis
C6/C7 deficiency N.A. M 12 Pneumonia, recurrent otitis and recurrent herpes zoster
carriers of mutations causing c2 deficiency and clinical manifestations
Carrier of C2 def. Heterozygous c.841_849 + 19del M 44 Purulent meningitis
Carrier of C2 def. Heterozygous c.841_849 + 19del M 43 Recurrent sinusitis
Carrier of C2 def. Heterozygous c.841_849 + 19del + c.945G>C F 9 Recurrent impetigo
Carrier of C2 def. Heterozygous c.2024G>T F 4 Pneumonia
Carrier of C2 def. Heterozygous c.841_849 + 19del F 10 Recurrent otitis
FigUre 2 | (a) Comparison of CH50 between subjects with homozygous or compound heterozygous mutations in C2 and heterozygous carriers of C2 deficiency. 
(B) Comparison of CH50 between subjects with homozygous mutations in C8 and carriers of heterozygous mutation causing C8 deficiency. (c) Comparison of 
AH50 between subjects with homozygous mutations in C8 and carriers of heterozygous mutation causing C8 deficiency.
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significantly lower CH50 than carriers of heterozygous mutation 
causing C2 deficiency (Figure 2A; p = 0.000001).
Subjects with homozygous mutations in C8 consistently had 
CH50 and AH50 below lower normal limit and significantly 
lower AH50 than carriers of heterozygous mutation causing 
C8 deficiency (Figures 2B,C; p = 0.094 for CH50; p = 0.002 for 
AH50).
In five subjects with C6, C7 and combined C6/C7 CD average 
CH50 was 7%, while average AH50 in these and one patient with 
properdin deficiency was 14%.
FigUre 4 | (a) Comparison of CH50 between patients with complete C2 deficiency with infections, complete C2 deficiency without infections patients with partial 
C2 deficiency with infections, and subjects with partial C2 deficiency without infections. (B) Comparison of AH50 between patients with complete C2 deficiency with 
infections, complete C2 deficiency without infections, patients with partial C2 deficiency with infections, and subjects with partial C2 deficiency without infections. 
(c) Comparison of C2 concentration between patients with complete C2 deficiency with infections, complete C2 deficiency without infections, patients with partial 
C2 deficiency with infections, and subjects with partial C2 deficiency without infections.
FigUre 3 | (a) Comparison of CH50 between patients with complete CD with infections, complete CD without infections, patients with partial CD with infections, 
and subjects with partial CD without infections. Patients with hereditary angioedema (HAE) and properdin deficiency are excluded. (B) Comparison of AH50 
between patients with complete CD with infections, complete CD without infections, patients with partial CD with infections, and subjects with partial CD without 
infections. Patients with HAE and CD not affecting AH50 are excluded.
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comparison of results of Functional 
complement Tests and concentrations of 
affected complement components 
Between (a) Patients With complete cD 
With infections; (b) subjects With 
complete cD Without infections; (c) 
Patients With Partial cD With infections; 
(d) subjects With Partial cD Without 
infections (Patients With hae are 
excluded)
Patients with complete CD with infections consistently had 
CH50 below lower normal limit and significantly lower than 
subjects with partial CD with (p = 0.012) or without infections 
(p  =  0.000002). Patients with partial CD with infections had 
significantly lower CH50 than subjects with partial CD without 
infections (p = 0.048) (Figure 3A). Patients with HAE and prop-
erdin deficiency were excluded. Patients with complete CD with 
infections consistently had AH50 below lower normal limit and 
significantly lower than subjects with partial CD without infec-
tions (p = 0.0008) (Figure 3B). Patients with HAE and CD not 
affecting AH50 were excluded.
Patients with complete C2 deficiency with infections con-
sistently had CH50 below lower normal limit and significantly 
lower than subjects with partial C2 deficiency with (p = 0.011) 
or without infections (p  =  0.000001). Difference in CH50 
between patients with partial C2 deficiency with infections 
and subjects with partial C2 deficiency without infections was 
not significant (p = 0.070) (Figure 4A). Patients with complete 
FigUre 5 | (a) Comparison of CH50 between patients with complete C8 deficiency with infections, complete C8 deficiency without infections, patients with partial 
C8 deficiency with infections, and subjects with partial CS deficiency without infection. (B) Comparison of AH50 between patients with complete C8 deficiency with 
infections, complete C8 deficiency without infections, patients with partial C8 deficiency with infections, and subjects with partial C8 deficiency without infection.  
(c) Comparison of C8 concentration between patients with complete C8 deficiency with infections, complete C8 deficiency without infections, patients with partial 
C8 deficiency with infections, and subjects with partial CS deficiency without infection.
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and partial C2 deficiency had median AH50 within normal 
limits and differences between subgroups were not significant 
(Figure 4B). Patients with complete and partial C2 deficiency 
had median C2 concentration below normal limits regardless of 
presence of infections. Patients with complete C2 deficiency had 
significantly lower C2 concentration than both patients with 
partial C2 deficiency with infections (p  =  0.01) and subjects 
with partial C2 deficiency without infections (p = 0002); how-
ever, the difference in C2 concentration between patients with 
partial C2 deficiency with infections and subjects with partial 
C2 deficiency without infections was not significant (p = 0.67) 
(Figure 4C).
Patients with complete C8 deficiency with infections consist-
ently had CH50 below lower normal limit. Median CH50 of 
subjects with partial C8 deficiency without infections was below 
lower normal limit and the difference in CH50 between patients 
with complete C8 deficiency with infections and subjects with 
partial C8 deficiency without infections was not significant 
because of low sample size (p = 0.094) (Figure 5A).
Patients with complete C8 deficiency with infections had 
median AH50 and C8 concentration below lower normal 
limit; however, subjects with partial C8 deficiency without 
infections had AH50 close to lower normal limit and C8 
concentration below lower normal limit. However, the differ-
ence in AH50 between the groups was significant (p = 0.002) 
(Figures 5B,C).
novel Mutations in C2 gene
Two novel mutations in C2 gene were identified in this study. The 
first was heterozygous substitution NM_000063: c.1754A>C 
in exon 14 which changes conserved amino acid threonin at 
position 585 into methionine (NP_000054.2 p.Thr585Met). 
Mutation pathogenicity was predicted through several in silico 
prediction tools: SIFT (deleterious 0.011), Polyphen2 (probably 
damaging 0.9), CADD score (33), and Mutation taster (disease 
causing 0.999). Variant is not present in dbSNP, ExAC, and 
gnomAD databases. All three subjects with this mutation who 
were also heterozygous for common 28 bp deletion, had severely 
reduced CH50 to the range of two homozygous pathogenetic 
mutations.
The second novel mutation found in exon 16 is a heterozygous 
missense mutation NM_000063: c.2024G>T which changes 
conserved amino acid cysteine at position 675 into phenylalanine 
(NP_000054.2 p.Cys675Phe). Mutation pathogenicity was pre-
dicted with several in silico programs: SIFT (deleterious 0.016), 
Polyphen2 (possibly damaging 0.902), CADD score (30), and 
Mutation taster (disease causing 0.999). Variant is not present in 
dbSNP, ExAC and gnomAD databases. We have identified only 
one carrier of this mutation who had reduced both average CH50 
(38%) and C2 concentration (10 mg/L) to the range that would be 
expected for a carrier of a pathogenetic mutation in C2.
comparison of ch50 Between specific 
Mutations in C2
Analysis of correlation between known pathogenetic mutation 
(28  bp deletion) and novel mutation (c.1754A>C) in C2 (pre-
sented in Figure  6) showed comparable reduction in CH50 in 
both mutations. Another novel mutation in C2 (c.2024G>T) was 
not present in homozygous form; however, average CH50 in a 
carrier of this mutation was 38%, a reduction consistent with 
pathogenetic heterozygous mutation (see Figure 2A).
combined c6/c7 Deficiency
At the time of the study, there was only one patient with combined 
C6 and C7 deficiency included in the Slovenian PID registry. 
Subtotal C6 deficiency was previously reported, in some cases 
combined with subtotal C7 deficiency (13).
c1 inhibitor Function and concentration in 
Patients With hae
The median C1 inhibitor concentration and function were 
0.188 mg/L (range 0.048–0.66) and 16% (range 1–64%), respec-
tively. Concentration of C4 was 0.089 mg/L (range 0.048–0.154).
FigUre 6 | Comparison of CH50 between subjects with C2 deficiency, 
according to underlying genetic defect.
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DiscUssiOn
In this study, we conducted analysis of prevalence of CD and 
demographic characteristics of patients with CD in Slovenia, 
with special focus on correlation of clinical manifestations 
with complement laboratory analysis at functional, protein, 
and genetic levels. Despite high prevalence of mutations in 
complement genes [the most common are mutations in C2 with 
a prevalence about 1:20,000 individuals (14)], CD represent 
only a minority of all PID in most national PID registries. Only 
16 out of 3,083 (0.5%; year 2009), 13 out of 1,368 (0.9%; year 
2012), 4 out of 147 (2.7%; year 2010), and 16 out of 348 (4.6%; 
year 2014) patients with CD were registered in the French (15), 
German (16), Greek (17), and Swiss (18) national PID registries, 
respectively. Low prevalence of CD was observed in the ESID 
registry as well. The percentage of CD increased from 0.5% of 
1,173 patients in 2005 to 4.9% of 19,091 patients in 2014 (http://
esid.org/Working-Parties/Registry/ESID-Database-Statistics). 
Prevalence of HAE in Slovenia (1:80,000) is similar to other 
reports (1:50,000) (8, 9). In contrast to low prevalence of CD 
in other reports, the frequency of CD is significantly higher in 
the Slovenian PID registry, where 26% (68 of 257) of all patients 
with PID represent patients with CD. Functional complement 
tests can be temporary reduced in subjects without CD because 
of complement consumption or improper transport; therefore, 
only patients with persistently reduced functional comple-
ment tests were included in the Slovenian PID registry, which 
increases reliability of epidemiologic PID data. Diagnosis of CD 
was genetically confirmed in all patients with CD in the registry 
for whom genetic testing was possible (45% of all registered 
patients with complement component deficiency) and in 96% 
of patients with HAE. True prevalence of CD, as calculated 
from genetic studies in unselected populations, is at least 10 
times higher than reported (14), meaning that there could still 
be unrecognized patients with CD. Low number of recognized 
patients with complement component deficiency could be a 
consequence of under-recognition because patients with bacte-
rial infections of the respiratory system and autoimmunity are 
not evaluated for CD. High percentage of neisserial (47% had 
N. meningitidis infection before CD diagnosis) in the European 
CD cohort probably reflects that complement analysis is regu-
larly performed only after neisserial infections (6). Unavailability 
of laboratory facilities to determine classical and alternative 
pathways and problems related to in vitro complement activa-
tion due to inappropriate handling of samples during transport 
limit complement evaluation as well (19). Another reason for 
under-recognition could be absence of infections until adult-
hood in some patients with CD (20). In addition, patients with 
CD vaccinated against encapsulated bacteria (S. pneumoniae, 
H.  influenzae type b, N. meningitidis) might not be diagnosed 
with CD, because these characteristic infections would be pre-
vented (21). However, delay in diagnosis of CD is associated with 
increased morbidity and an older age at diagnosis is significantly 
associated with mortality (20). Therefore, awareness campaigns 
about CD in PID community should be promoted to improve 
timely recognition of CD worldwide. The number of labora-
tories performing complement function tests should increase 
to improve the availability for screening more patients with 
infections with encapsulated bacteria and autoimmune disease. 
Health-care providers should be aware that handling of blood 
samples, including collection and storage are critically important 
for some of the complement assays (19).
Correct identification of subjects with CD with increased risk 
for clinical manifestations is crucial as it is possible to significantly 
lower the risk of severe respiratory infections, sepsis and menin-
gitis with vaccination against S. pneumoniae, H. influenzae type b, 
and N. meningitidis and shorten delay of diagnosing autoimmune 
disease. In contrast to the European cohorts of CD, where CD was 
usually diagnosed after bacterial meningitis (6, 22), complement 
component deficiency (especially C2 deficiency) was diagnosed 
in many Slovenian patients after recurrent bacterial infections of 
respiratory system (Table 1). The presenting infectious features 
of 23 Slovenian patients with C2, C6, C6/7, C8, and properdin 
deficiencies were pneumonia (10 pt) sepsis (9 pt), purulent men-
ingitis (7 pt), otitis (4 pt), cellulitis (2pt) and impetigo, sinusitis, 
and herpes zoster each in 1 patient (Table  1). These results 
implicate that limiting complement evaluation to patients with 
meningitis could account for under-recognition of CD. It should 
be stressed that many infections in our cohort were recurrent 
(pneumonia 6 pt, otitis 4 pt, sepsis 2 pt, purulent meningitis 2 pt, 
herpes zoster 1 pt).
Not only patients with infections but also patients with auto-
immunity should be screened for CD as C2 deficiency is detected 
in about 1% of Caucasian patients with SLE (23). However, 
autoimmunity was observed only in 1 out of 17 patients with 
genetically confirmed C2 deficiency in Slovenian PID registry. 
CD was diagnosed when the patient was evaluated for glomerulo-
nephritis presenting in infancy, 2 weeks after vaccination against 
diphtheria, tetanus, pertussis, polio, and H. influenzae type b.
Laryngeal edema is an important cause of mortality in patients 
with HAE; therefore, relatives of patients with HAE should be 
evaluated for HAE before life-threatening complications occur.
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The Power of Functional complement 
Tests in Differentiating complete and 
Partial cD
In the past decades, identification of CD was only possible with 
functional complement tests, but nowadays more subjects with CD 
are expected to be diagnosed through next generation sequenc-
ing. Therefore, it is important to know the correlation between 
mutations in complement system, complement functional studies 
and risk for infections in subject with CD. Our study confirmed 
previous reports that results of complement functional tests dif-
ferentiate subjects with homozygous mutations in complement 
genes from heterozygous carriers (19).
Additional strength of the present study is the finding that 
functional tests can predict the risk for characteristic infections 
even in subgroups of subjects with partial reduction of comple-
ment (carriers of heterozygous mutation causing mutation in CD 
genes). Patients with partial CD with characteristic infection had 
significantly lower CH50 than subjects with partial CD without 
infections. This was not observed in previous studies, where 
heterozygous carriers of CD in general did not have significantly 
increased risk of infections (5, 20). In our patients, complement 
functional studies better correlated with characteristic infections 
than concentrations of affected complement component; there-
fore, we suggest performing CH50 and AH50 tests in all subjects 
with CD and protection with vaccines to all subjects with more 
than borderline reduction of complement functional studies.
novel Mutations
Patients with novel c.1754C>T mutation had profoundly reduced 
CH50 that was not different to CH50 in patients with known 
deleterious homozygous deletion of 28bp. The carrier of another 
novel mutation c.2024G>T had reduced both average CH50 and 
C2 concentration to the range that would be expected for a carrier 
of a pathogenetic mutation in C2.
However, normal C2 concentration was observed in a family 
member with compound heterozygous mutations c.945G>C and 
c.1754C>T, which is consistent with previous observation that 
c.945G>C mutation is a non-deleterious polymorphism (4, 24).
cOnclUsiOn
Complement deficiency may be widely under-recognized and 
should be suspected in any patient with recurrent or severe infec-
tions with encapsulated bacteria and in patients with autoimmun-
ity, especially SLE and glomerulonephritis. This study showed that 
complete CD predicts homozygous or compound heterozygous 
deleterious mutations in complement genes, while partial CD pre-
dicts heterozygous carrier state. Furthermore, risk for characteristic 
infections can be predicted according to the results of complement 
functional tests even in carriers of heterozygous mutation causing 
CD. Observed prevalence of characteristic infections in heterozy-
gous CD carriers with reduced complement activity supports active 
protection through vaccination against encapsulated bacteria not 
only in patients with CD but also in subjects with partial CD. 
Screening of family members of subjects with CD is recommended 
not only for patients with deficiency of complement components, 
but also in patients with HAE, because morbidity and mortality 
in patients with HAE can be reduced with available preventive 
measures, especially before surgical procedures close to airway.
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